Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Case report: ‘AARS2 leukodystrophy’

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The impact of consanguinity on the frequency of inborn errors of metabolism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Residual OCTN2 transporter activity, carnitine levels and symptoms correlate in patients with primary carnitine deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Alexithymia, Emotional Distress, and Perceived Quality of Life in Patients With Hashimoto's Thyroiditis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Robert J Hopkin
  • Ulla Feldt-Rasmussen
  • Dominique P Germain
  • Ana Jovanovic
  • Ana Maria Martins
  • Kathleen Nicholls
  • Alberto Ortiz
  • Juan Politei
  • Elvira Ponce
  • Carmen Varas
  • Frank Weidemann
  • Meng Yang
  • William R Wilcox
Vis graf over relationer

Background: Fabry disease is an inherited disorder of glycolipid metabolism with progressive involvement of multiple organs, including the gastrointestinal tract, in classically affected male patients. Clinical presentations in males with later-onset Fabry phenotypes are more heterogeneous and largely dependent on the level of residual α-galactosidase A activity.

Methods: We assessed agalsidase beta treatment outcomes of gastrointestinal symptoms in adult males with classic or later-onset Fabry disease. Self-reports of abdominal pain and diarrhea ('present'/'not present' since previous assessment) at last clinical visit (≥0.5 year of follow-up) were compared with treatment-baseline.

Results: Classic male patients were considerably younger at first treatment than the fewer males with later-onset phenotypes (36 vs. ~47 years) and reported gastrointestinal symptoms more frequently at baseline (abdominal pain: 56% vs. 13%; diarrhea: 57% vs. 23%). As compared with baseline, significantly fewer classic patients reported abdominal pain after a median of 4.7 years of treatment (N = 171, 56% vs. 41%, P < 0.001). Moreover, significantly fewer patients reported diarrhea after 5.5 years of follow-up (N = 169, 57% vs. 47%, P < 0.05). Among the males with later-onset phenotypes, albeit statistically non-significant, abdominal pain reports reduced after a median of 4.2 years (N = 48, 13% vs. 4%) and diarrhea reports reduced after a median of 4.4 years of treatment (N = 47, 23% vs. 13%).

Conclusions: Sustained treatment with agalsidase beta was associated with improvement in abdominal pain and diarrhea in a significant proportion of classic male Fabry patients. Males with later-onset phenotypes reported gastrointestinal symptoms much less frequently at baseline as compared with classic patients, and non-significant reductions were observed.

OriginalsprogEngelsk
TidsskriftMolecular Genetics and Metabolism Reports
Vol/bind25
Sider (fra-til)100670
ISSN2214-4269
DOI
StatusUdgivet - dec. 2020

Bibliografisk note

© 2020 Published by Elsevier Inc.

ID: 61807938